Compare CXAI & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CXAI | MBAI |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9M | 10.6M |
| IPO Year | N/A | N/A |
| Metric | CXAI | MBAI |
|---|---|---|
| Price | $0.26 | $1.66 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 10.0M | 48.1K |
| Earning Date | 04-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $70.21 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $1.31 |
| 52 Week High | $1.49 | $3.92 |
| Indicator | CXAI | MBAI |
|---|---|---|
| Relative Strength Index (RSI) | 56.23 | 47.62 |
| Support Level | $0.24 | $1.38 |
| Resistance Level | $0.38 | $1.89 |
| Average True Range (ATR) | 0.04 | 0.15 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 62.38 | 24.05 |
CXApp Inc is a provider of AI-powered employee experience solutions, delivering enterprise-grade software that enhances workplace engagement, productivity, and operational efficiency. The company's flagship product, the CXAI Platform, provides a comprehensive suite of tools designed to empower employees and enable organizations to create smarter workplaces. The product's key components include CXAI Apps, CXAI BTS, and CXAI-VU. The company generates the majority of its revenue from Licenses.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.